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Over the past 25 years, successive cloning of SLC34A1, SLC34A2 and SLC34A3,  which encode the 
sodium-dependent inorganic phosphate (Pi) cotransport proteins 2a–2c,has  facilitated the 
identification of molecular mechanisms that underlie the regulation of renal and intestinal Pi 
transport. Pi and various hormones, including parathyroid hormone and phosphatonins, such 
as fibroblast growth factor 23, regulate the activity of these Pi transporters through 
transcriptional, translational and post-translational mechanisms involving interactions with 
PDZ domain-containing proteins, lipid microdomains and acute trafficking of the transporters 
via endocytosis and exocytosis. In humans and rodents, mutations in any of the three transporters 
lead to dysregulation of epithelial Pi transport with effects on serum Pi levels and can cause 
cardiovascular and musculoskeletal damage, illustrating the importance of these transporters in 
the maintenance of local and systemic Pi homeostasis. Functional and structural studies have 
provided insights into the mechanism by which these proteins transport Pi, whereas in vivo and     
ex vivo cell culture studies have identified several small molecules that can modify their 
transport function. These small molecules represent potential new drugs to help maintain Pi 
homeostasis in patients with chronic kidney disease — a condition that is associated with 






• In the past 25 years, the cloning of SLC34A1, SLC34A2 and SLC34A3, which 
encode the Na+-dependent inorganic phosphate (Pi) cotransporters NaPi-IIa, 
NaPi-IIb and NaPi-IIc, respectively, has enabled study of the molecular 
mechanisms that underlie the regulation of renal and intestinal Pi transport. 
• Dietary factors, particularly dietary Pi, as well as hormones and phosphatonins, 
including parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), 
regulate the expression and activity of the Pi transporters through 
transcriptional, translational and post-translational mechanisms that involve 
interactions with PDZ domain-containing proteins, lipid microdomains and 
acute trafficking via endocytosis or exocytosis. 
• Mutations in any of the three transporters can cause dysregulation of epithelial 
Pi transport, can affect serum Pi levels and can cause damage of various target 
organs in both humans and rodents, highlighting the importance of these 
transporters in the maintenance of local and systemic Pi homeostasis. 
• Functional studies together with structure–function studies have provided 
insights into the transport mechanisms of the NaPi-II cotransporter. 
• The development of small molecules that modify the activity of Pi transporters 
holds promise for the maintenance of Pi homeostasis in patients with chronic 
kidney disease and other disorders associated with hyperphosphataemia and 




Since the identification of the major renal inorganic phosphate (Pi) transporter, 
encoded by SLC34A1, in 1993, advances in molecular and cell biology and biophysical 
and microscopy techniques have facilitated detailed study of the molecular 
mechanisms of renal and intestinal Pi transport. Impairment of renal and intestinal Pi 
transport results in hypophosphataemia, which leads to the dysfunction of several 
organ systems, including the musculoskeletal system. Conversely, dysregulation of 
renal and intestinal Pi transport, for example, as occurs in the setting of chronic kidney 
disease (CKD), results in hyperphosphataemia, which has major consequences for 
cardiovascular function and soft tissue calcification. Tight regulation of renal and 
intestinal Pi transport and Pi homeostasis is therefore crucial for normal organ function. 
Before the identification of the Pi transporters, transport assays involving 
micropuncture of the intact renal proximal tubule and of isolated brush-border 
membrane vesicles (BBMVs) from renal and intestinal tissue identified the presence 
of a Na+-dependent Pi flux across the luminal membranes of the respective 
epithelia1,2,3. These seminal investigations also provided new insights into the 
importance of the renal Pi reabsorption pathway in maintaining Pi homeostasis. 
Specifically, these studies demonstrated the dependence of renal Pi transport on 
parathyroid hormone (PTH), luminal pH and Pi itself4,5. However, many questions 
about the mechanisms of Pi transport remained unanswered; in particular, the 
molecular identity of the carrier proteins was unknown. In 1993, SLC34A1, which 
encodes the renal Na+-dependent Pi cotransporter 2a (NaPi-IIa; also known as 
NPT2a), was successfully cloned from rat and human tissue using a Xenopus laevis 
oocyte expression system6. This success was followed in 1998 by the cloning of a 
second Na+-dependent Pi cotransporter, NaPi-IIb (also known as NPT2b; encoded by 
Slc34a2) from mouse intestine7. The third member of the family, the renal NaPi-IIc 
(also known as NPT2c; encoded by Slc34a3), was cloned from mouse kidney tissue 
in 2002 (ref.8). These three isoforms have different tissue distributions, with NaPi-IIa 
and NaPi-IIc being expressed in kidney and NaPi-IIb being expressed in intestine and 
other tissues (Table 1). The critical role of the two renal isoforms in maintaining Pi 
homeostasis has been confirmed through gene knockout studies9,10,11 and from 
studies of humans with naturally occurring mutations. In addition to NaPi-II 
transporters, the two members of the SLC20 family of Na–Pi cotransporters, namely, 
PIT1 (encoded by SLC20A1) and PIT2 (encoded by SLC20A2), are expressed (among 
other tissues) in renal and intestinal tissues, although their regulation and overall 
contribution to Pi homeostasis remains only partially understood12. 





NaPi-IIb (SLC34A2)  
NaPi-IIc 
(SLC34A3)  
Tissue distribution  Kidney, bone  
Gut, lung, liver, mammary gland, 
salivary gland, thyroid and testes  
Kidney  
Driving cations  Na+ (Li+)  Na+(Li+)  Na+  
Electrogenic (charge 
per cycle)  
Yes (1)  Yes (1)  No (0)  
Stoichiometry (Na:Pi)  3:1  3:1  2:1  
NaPi, Na+-dependent Pi cotransporter; Pi, inorganic phosphate. 
In this Review, we describe the mechanisms by which dietary, hormonal and metabolic 
factors regulate the expression and function of NaPi-II transporters and how 
understanding of their structure–function relationships has provided insights into the 
mechanisms by which they transport Pi. We also discuss the consequences of 
dysregulated Pi transport and how the identification of small molecules that can modify 
Pi transport might aid in the development of new agents to maintain Pi homeostasis in 
patients with CKD. 
 
Dietary factors and metabolic acidosis 
Pi itself, including Pi from dietary sources, is a major regulator of NaPi-II transporter 
function. Moreover, dietary potassium (K) and changes in pH resulting from metabolic 
acidosis contribute to the regulation of Pi homeostasis. 
Dietary Pi  
Under normal physiological conditions and in the context of normal kidney function, 
maintenance of Pi homeostasis and serum Pi levels are primarily mediated through 
regulated reabsorption of Pi by the kidney and to a lesser extent through absorption of 
Pi in the intestine. Dietary Pi is a major regulator of renal Pi reabsorption. Dietary 
restriction of Pi results in a rapid adaptive increase in Pi reabsorption mediated by 
sequential upregulation of NaPi-IIa expression, followed by NaPi-IIc, and eventually 
PIT2 in the brush-border membrane (BBM) of the renal proximal tubule8,13,14. 
Conversely, ingestion of a high-Pi diet induces rapid downregulation of NaPi-IIa, 
followed by NaPi-IIc and PIT2 (ref.14). NaPi-IIa is not recycled, and after endosomal 
internalization it is degraded in lysosomes15. By contrast, NaPi-IIc accumulates 
subapically and is most likely partially recycled16, although the renal adaptation of 
NaPi-IIc and PIT2 to dietary changes in Pi is not well understood. Trafficking of NaPi-
IIa and NaPi-IIc to the apical BBM of proximal tubular epithelial cells in response to 
low dietary Pi involves microtubule-dependent translocation16,17, as well as interactions 
of the transporters with the PDZ domain-containing proteins sodium–hydrogen 
antiporter 3 regulating factor 1 (NHERF1; also known as EBP50) and NHERF3 (also 
known as PDZK1)18,19,20,21 (Fig. 1), as discussed later. 
 
The adaptation of renal Pi reabsorption to acute variations in dietary Pi levels does not 
involve alterations in RNA levels of the transporters. However, persistent changes in 
Pi concentration as a result of chronic alterations in dietary Pi intake alter the 
transcription and translation of NaPi transporters, leading to increased or decreased 
RNA and protein levels22. The adaptive changes of the kidney to acute and chronic 
dietary Pi are accompanied by modifications in the concentration of several hormones 
and other factors such as PTH, fibroblast growth factor 23 (FGF23), 1,25-dihydroxy-
vitamin D3 (1,25(OH)2D3), insulin and dopamine (reviewed elsewhere23,24). However, 
only PTH seems to be necessary for the early adaptation of renal NaPi transport to 
high dietary Pi (ref.25) (discussed later). 
Dietary potassium 
K+ deficiency and resultant hypokalaemia occur as a consequence of decreased 
dietary intake, decreased intestinal K+ absorption and increased urinary K+ secretion 
resulting from diuretic use or tubular transport defects. Deficiency of K induces an 
increase in urinary Pi excretion that is mediated, at least in part, via decreased Na–Pi 
cotransport activity in the BBM of the renal proximal tubule26. This decrease in Na–Pi 
cotransport activity occurs despite increased BBM expression of NaPi-IIa and PIT1 
owing to a decrease in the lateral diffusion and increased clustering of these 
transporters in the BBM, hindering their activity27. By contrast, dietary K+ deficiency 
decreases BBM expression of NaPi-IIc and PIT2 (ref.28), suggesting that the 
mechanisms by which dietary K+ regulates Na–Pi transport are complex. 
Metabolic acidosis 
Metabolic acidosis increases urinary excretion of Pi, which aids the removal of acid 
from the blood29,30. However, studies into the mechanisms underlying the 
phosphaturia have yielded conflicting findings. In rats, chronic metabolic acidosis 
(for ≥ 12 h) achieved by administration of NH4Cl in both food and drinking water led to 
progressively decreased BBM Na–Pi cotransport activity as a result of impaired 
transcription and translation of NaPi-IIa29. These effects of metabolic acidosis on NaPi 
transporter expression are blunted by a low-Pi diet, which counteracts the effects of 
acidosis on NaPi-IIa expression31. Rats with acute metabolic acidosis (for ≤ 6 h) also 
exhibit a decrease in BBM Na–Pi cotransport activity; however, this decrease is 
independent of changes in Slc34a1 mRNA expression29. Rather, the decrease in 
NaPi-IIa protein expression resulting from acute metabolic acidosis is probably 
mediated by changes in NaPi-IIa trafficking through enhanced internalization from 
and/or impaired delivery of NaPi-IIa to the apical BBM29,31. Another study showed that 
unlike wild-type mice, NaPi-IIa-null mice do not exhibit a transient increase in urinary 
Pi excretion in response to 2 days of acid loading30. However, in contrast to the above-
described studies29,31, this study found that acidosis increased the expression of NaPi-
IIa in the BBM of wild-type mice and the expression of NaPi-IIc in both wild-type and 
NaPi-IIa-null animals30. The phosphaturia observed during acidosis might therefore 
not be a consequence of reduced transporter expression but rather result from a direct 
inhibitory effect of acidosis on transport function30. 
Regulation of NaPi-II by hormones 
The capacity of the kidney to reabsorb Pi is under tight hormonal control. This control 
is mostly mediated via hormonally induced regulation of the abundance of NaPi-II 
cotransporters in the proximal tubule BBM. 
PTH 
PTH is an important regulator of Na–Pi cotransport. It markedly increases urinary Pi 
excretion and decreases renal Pi reabsorption by altering the abundance of NaPi-IIa, 
NaPi-IIc and PIT2 in the BBM. Administration of PTH to mice and rats induces rapid 
(within minutes) removal of NaPi-IIa protein from the BBM without any corresponding 
change in mRNA levels17,32,33. Likewise, PIT2 is removed from the BBM of mice within 
60 min of PTH treatment34. However, PTH-induced removal of NaPi-IIc from the BBM 
takes hours35, as discussed below. 
The removal of NaPi-IIa from the BBM in response to PTH requires phosphorylation 
of the PDZ domain-containing protein NHERF1 (ref.36). This phosphorylation 
destabilizes the association of NHERF1 with NaPi-IIa, allowing removal of the 
cotransporter from the BBM19. Notably, several point mutations in NHERF1 (also 
known as SLC9A3R1) have been identified in humans, some of whom have 
nephrolithiasis or bone mineralization defects37. Transfection of mutant NHERF1 
cDNA into a kidney tubule cell line increased the responsiveness of NaPi-IIa to PTH, 
resulting in a significant decrease in phosphate uptake and suggesting that mutations 
of NHERF1 might contribute to the pathogenesis of renal loss of Pi (ref.37). 
In addition to regulating the trafficking and stabilization of NaPi-IIa in the apical BBM, 
NHERF1 also mediates PTH-receptor-induced activation of phospholipase C (PLC), 
which is important for PTH-mediated internalization of NaPi-IIa38,39,40. Several 
signalling cascades are involved in the PTH-induced removal of NaPi-IIa from the 
BBM. PTH signals through PTH1 receptors located at the apical and basolateral 
membranes of the renal proximal tubule. Activation of basolateral PTH1 receptors 
increases cAMP levels and stimulates protein kinase A (PKA)-dependent pathways, 
whereas activation of apical PTH1 receptors couples to PLC and therefore results in 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and activation of 
protein kinase C (PKC)34,41. NHERF1, which is specifically expressed in the apical 
membrane, links the PTH1 receptors with PLC and is responsible for the different 
intracellular signalling elicited by apical and basolateral receptors39. The response of 
NaPi-IIc to PTH also involves PKA and PKC because downregulation of the 
cotransporter is observed in mice following administration of PTH fragments that 
activate only PKC or PKA and PKC34,35. In addition to PKA and PKC, the mitogen-
activated protein kinases extracellular-signal regulated kinase 1 (ERK1) and ERK2 are 
thought to contribute to PTH-induced regulation of Na–Pi cotransport42,43. 
After its removal from the BBM in response to PTH, NaPi-IIa is transported via clathrin-
coated pits to early and late endosomes and then to lysosomes for degradation17,44,45. 
By contrast, although treatment with PTH induces internalization of NaPi-IIc35 and 
PIT2 (ref.34), the fate of these transporters remains unknown. 
As mentioned above, PTH induces a rapid decrease in the expression of NaPi-IIa 
protein in the BBM through endocytosis. Concomitantly, NaPi-IIa accumulates in 
endosomes, whereas microtubules form dense bundles in an apical-to-basal 
orientation46. This bundling of microtubules is thought to be a general feature of rapid 
endocytosis, and it is consistent with microtubular-dependent trafficking of internalized 
cotransporters along the endocytic pathway. After 60 min of PTH action, the tubule 
cells are vastly depleted of NaPi-IIa owing to lysosomal degradation of internalized 
transporters, at which point their microtubular cytoskeleton returns to normal46. 
Prevention of the microtubule rearrangement by administration of the microtubule-
stabilizing agent paclitaxel induced NaPi-IIa to accumulate in the subapical portion of 
the cell, delaying its depletion46. The accumulation of NaPi-IIa in the subapical portion 
of the cell was associated with expansion of the dense apical tubules of the subapical 
endocytic apparatus (SEA), suggesting that PTH-induced downregulation of NaPi-IIa 
occurs through an endocytic process that involves internalization of the transporter 
into the SEA and delivery of the transporter to lysosomes for degradation46. 
Use of total internal reflection fluorescence (TIRF) microscopy has shown that a 
dynamic actin cytoskeleton is required for the removal of NaPi-IIa from the BBM in 
response to PTH. In addition, these imaging studies have shown that myosin VI — a 
myosin motor that is co-regulated with NaPi-IIa — is necessary for PTH-induced 
removal of NaPi-IIa from BBM microvilli47. 
A number of imaging techniques, including TIRF, modulation tracking (or nanoscale 
precise imaging by rapid beam oscillation (nSPIRO)), raster image correlation 
spectroscopy (RICS) and number and brightness (N&B) analysis, have been used to 
study the differential modulation of NaPi-IIa and NaPi-IIc by PTH. These studies have 
demonstrated that expression of both NaPi-IIa and NaPi-IIc in the apical membrane of 
renal proximal tubule cells is decreased in response to PTH, but as mentioned earlier, 
the removal of NaPi-IIc from the apical BBM is much slower than for NaPi-IIa48. 
Analysis of the diffusion coefficients of the two transporters suggests that NaPi-IIc 
remains tethered within the apical membrane for longer than NaPi-IIa following PTH 
treatment, accounting, at least in part, for the difference between the two transporters 
in their response to PTH48 (Fig. 1). 
1,25-Dihydroxy-vitamin D3  
The active form of vitamin D, 1,25(OH)2D3, has also been shown to increase proximal 
tubular Pi reabsorption49. Compared with levels in wild-type mice, concentrations of 
1,25(OH)2D3 are elevated in NaPi-IIa-deficient mice, presumably to compensate for 
urinary Pi waste50. Whether 1,25(OH)2D3 has direct effects on NaPi transporters is, 
however, controversial as vitamin D status is closely associated with alterations in 
plasma levels of Ca2+, PTH, FGF23 and Klotho — factors that all affect Pi transport. 
1,25(OH)2D3 also increases intestinal Pi absorption. Interestingly, both intestinal and 
renal adaptations to a low-Pi diet are conserved in vitamin D3 receptor (VDR)-knockout 
mice51; however, these mice exhibit hypophosphataemia and hyperphosphaturia51, 
suggesting that renal tubular Pi reabsorption is impaired. Compared with age-matched 
wild-type mice, VDR-knockout mice demonstrate decreased renal Na–Pi cotransport 
activity and considerably lower NaPi-IIa, NaPi-IIc and PIT2 protein levels following 
weaning52. However, intervention with a rescue diet containing a higher proportion of 
Pi and Ca2+ content to normalize PTH levels also normalized expression of the three 
transporters, indicating that lack of VDR activity per se does not impair renal Pi 
reabsorption. 
Glucocorticoids 
Glucocorticoids, including cortisone and dexamethasone, inhibit proximal tubule Na–
Pi transport in mice, rats and humans53,54. Conversely, adrenalectomy increases Pi 
reabsorption55. In rats, chronic dexamethasone treatment decreases Na–Pi transport 
by decreasing NaPi-IIa mRNA and protein expression in the BBM56. In line with the 
renal effects, glucocorticoids also inhibit intestinal Pi absorption, as well as the RNA 
and protein abundance of NaPi-IIb57. 
Oestrogen 
Oestrogen treatment has long been known to cause hypophosphataemia in humans58. 
Prolonged treatment of ovariectomized rats with oestrogen also decreases renal Pi 
reabsorption and results in hypophosphataemia. This decrease in proximal tubule Pi 
uptake is primarily the result of decreased NaPi-IIa mRNA and protein levels because 
NaPi-IIc expression is not affected59. In contrast to their effects in the kidney, 
oestrogens increase the intestinal absorption of Pi by increasing the RNA and protein 
expression of NaPi-IIb; however, this effect is not sufficient to counteract the 
hypophosphataemia resulting from the diminished renal expression of NaPi-IIa60. The 
effects of oestrogen on NaPi transporter expression are mediated by ERα and ERβ61. 
The phosphaturic effect of oestrogen might also be mediated through an increase in 
FGF23 synthesis, which results in decreased serum 1,25(OH)2D3 and Pi levels62; 
however, this indirect mechanism of action does not seem to operate in the intestine 
because administration of oestrogens increases Pi uptake in the Caco-2 intestinal cells 
in vitro60. 
Thyroid hormone 
Excess levels of thyroid hormone are associated with hyperphosphataemia63. Chronic 
treatment of thyroparathyroidectomized (TPTX) rats with thyroid hormone increases 
renal Na–Pi cotransport by increasing Slc34a1 mRNA transcription and levels of NaPi-
IIa protein in the BBM63. The NaPi-IIa gene, SLC34A1, contains a thyroid hormone 
response element, and administration of thyroid hormone to opossum kidney (OK) 
tubule cells increases NaPi-IIa expression, suggesting that the effects of thyroid 
hormone on this NaPi transporter are direct and independent of other hormones64. In 
addition to maintaining a basal level of phosphataemia through regulation of NaPi-IIa 
transcription, thyroid hormone seems to participate in the upregulation of Pi transport 
and NaPi-IIa expression at weaning because levels of the hormone and transporter 
are simultaneously increased in the transition between suckling and weaning in rats65. 
Regulation of NaPi by phosphatonins 
The term phosphatonins describes several factors that, in addition to PTH and 
1,25(OH)2D3, regulate Pi homeostasis. This family includes FGF23, polypeptide N-
acetylgalactosaminyltransferase 3 (GALNT3), phosphate-regulating neutral 
endopeptidase (PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin 
matrix acidic phosphoprotein 1 (DMP1), FGF7 and secreted frizzled-related protein 4 
(sFRP4). 
FGF23 
FGF23 is a hormone that is synthesized by osteocytes and osteoblasts. The mature 
(active) form of FGF23 (also termed ‘intact’ FGF23) is generated following removal of 
the 24-residue signal peptide at the amino terminal. Intact FGF23 can also undergo 
cleavage at a furin-like cleavage site (R176XXR179) to produce inactive amino-terminal 
and carboxy-terminal fragments. As discussed below, the identity of the 
endopeptidase responsible for cleaving FGF23 remains a matter of debate. 
A glycosylation site at T178 overlaps with the furin-like cleavage site, and O-
glycosylation of intact FGF23 blunts this cleavage, promoting the secretion of intact 
FGF23 (reviewed elsewhere66). Carboxy-terminal fragments can compete with the 
intact hormone for binding to FGF receptor (FGFR)–α-Klotho complexes and thereby 
antagonize intact FGF23 signalling. FGF23 synthesis is stimulated by high dietary or 
plasma Pi levels67 and by PTH68, 1,25(OH)2D3 (ref.69) and Ca2+ (ref.70). A number of 
other regulators have been identified in the past few years, including iron deficiency71, 
erythropoietin72, insulin73, AMP kinase74 and inflammatory cytokines75. 
FGF23 signalling requires the binding of the hormone to FGFR and α-Klotho76, leading 
to activation of FGFR substrate 2α (FRS2α), ERK1 and/or ERK2 and 
serum/glucocorticoid regulated kinase 1 (SGK1). FGF23 reduces reabsorption of Pi in 
the renal proximal tubule and reduces levels of 1,25(OH)2D3 by inhibiting 
renal 1,25(OH)2D3 synthesis by CYP27B1 and enhancing 1,25(OH)2D3 catabolism by 
CYP24A1 (ref.77). Because 1,25(OH)2D3 also stimulates intestinal absorption of Pi, its 
reduction decreases active Pi absorption. FGF23 also downregulates the abundance 
of NaPi-IIa, NaPi-IIc and PIT2 in the proximal tubule. The combined effect of blunted 
intestinal and renal (re)absorption is a reduction in plasma levels of Pi. Similar to PTH, 
FGF23 destabilizes the anchoring of NaPi-IIa to the apical membrane by promoting 
the phosphorylation of NHERF1 (ref.78). Whether the different Na–Pi cotransporters 
exhibit different kinetics in response to FGF23 as they do for PTH is currently 
unknown. 
Whereas PTH stimulates the production of FGF23, FGF23 negatively regulates the 
parathyroid gland, acting to inhibit the synthesis and/or release of PTH79. Studies in 
humans80 and rodents25 indicate that Pi loading induces an initial raise in plasma PTH 
levels, which precedes the increase in FGF23. In the absence of parathyroid glands, 
however, secretion of FGF23 may be accelerated25. Moreover, increased FGF23 
precedes the development of hyperparathyroidism in patients with CKD and acute 
kidney injury, suggesting that under some circumstances changes in FGF23 may 
precede the elevation in PTH81. 
Mutations within the R176XXR179 cleavage motif that enhance the half-life of intact 
FGF23 result in excessive urinary Pi loss and cause autosomal dominant 
hypophosphataemic rickets (ADHR; OMIM 193100)82. Secretion of high levels of 
FGF23 by mesenchymal tumours is one cause of tumour-induced osteomalacia (also 
known as oncogenic hypophosphataemic osteomalacia (OHO; OMIM 605912)), which 
presents with hypophosphataemia secondary to renal Pi wasting and inappropriately 
normal or even low 1,25(OH)2D3 levels83. Conversely, loss-of-function mutations in 
FGF23 cause familial tumoural calcinosis (FTC; OMIM 211900), which is 
characterized by reduced urinary excretion of Pi, hyperphosphataemia, normal or 
elevated 1,25(OH)2D3 levels and ectopic calcification84. FTC can also be caused by 
mutations in α-Klotho85. FGF23-deficient and α-Klotho-hypomorphic mice exhibit 
hyperphosphataemia, reduced urinary Pi excretion, increased expression of NaPi-IIa 
and NaPi-IIc at the BBM and high 1,25(OH)2D3 levels86. 
The effect of FGF23 on renal Na–Pi cotransporter expression largely depends on the 
presence of FGFR1 (ref.87), although a contribution of FGFR4 has also been 
reported88. FGFR1 probably also contributes to the FGF23-induced downregulation of 
PTH because this receptor (and α-Klotho) is downregulated in hyperplastic parathyroid 
glands from patients with uraemia89. In humans, gain-of-function mutations of FGFR1 
cause osteoglophonic dysplasia (OMIM 166250), which is associated with 
hypophosphataemia as a result of massive urinary Pi loss90. 
A cleaved form of α-Klotho called soluble α-Klotho, which lacks co-receptor activity 
and is present in plasma and urine, promotes phosphaturia and downregulates NaPi-
IIa even in the absence of FGF23 through a proteolytic mechanism that is dependent 
on its glucuronidase activity91. However, the crystal structure of a ternary complex 
consisting of human FGF23, the ligand-binding domain of FGFR1c and cleaved α-
Klotho suggests that the structure of α-Klotho within this complex cannot support 
glycosidase activity92. Thus, the effect of α-Klotho on FGF23 signalling seems to be 
independent of its enzymatic activity. Of note, whereas inactivating mutations in α-
Klotho can cause FTC85, a translocation mutation that results in high levels of α-Klotho 
causes hypophosphataemic rickets and hyperparathyroidism93. 
GALNT3 
GALNT3 is the glycosyltransferase that is responsible for O-glycosylation of FGF23 at 
T178, preventing its proteolytic processing and therefore allowing the secretion of 
intact FGF23 (ref.94). Mutations in GALNT3 are associated with FTC95. GALNT3-
deficient mice have reduced circulating levels of intact FGF23 (ref.96); they are also 
hyperphosphataemic, have inappropriately normal levels of 1,25(OH)2D3, reduced 
PTH and moderately upregulated Slc34a1 mRNA expression. Homozygous GALNT3-
deficient males are growth retarded and have increased bone mineral density. These 
phenotypes are partially normalized upon breeding with transgenic animals 
expressing a proteolysis-resistant form of human FGF23 (Arg176Gln) found in some 
patients with ADHR97, further suggesting that the GALNT3 transferase is required for 
proper secretion of intact FGF23. 
GALNT3 mRNA expression is stimulated by extracellular Pi and by 1,25(OH)2D3 in 
vitro98. Despite its stimulatory effect on FGF23 production, PTH inhibits expression of 
Galnt3 mRNA in mice99. Reduced GALNT3 results in higher levels of FGF7 (see 
below) and matrix metalloproteinases MMP8 and MMP9, which are both involved in 
ectopic calcification100. 
PHEX 
PHEX is a metalloendopeptidase that is mutated in patients with X-linked 
hypophosphataemic rickets (XLH; OMIM 307800)101, a condition characterized by high 
FGF23 levels, hyperphosphaturia, hypophosphataemia, rickets, short stature and limb 
deformities. The PHEX gene is located on the X chromosome and regulates the 
expression but not the degradation of FGF23. As discussed below, PHEX recognizes 
particular motifs (acidic serine aspartate-rich MEPE-associated motifs (ASARMs)) 
found in short integrin-binding ligand-interacting glycoproteins (SIBLING) proteins 
(reviewed elsewhere102). The expression of PHEX is downregulated by 1,25(OH)2D3 
in osteoblastic cell lines, whereas in osteocyte-like cells it is upregulated by 
extracellular Pi and 1,25(OH)2D3. Several mouse models carrying Phex mutations 
recapitulate the phenotype of XLH. In Hyp mice, for example (which have a mutation 
in Phex), urinary Pi loss correlates with elevated FGF23 levels and reduced expression 
of NaPi-IIa and NaPi-IIc at the renal proximal BBM103. Although PHEX was initially 
thought to be the protease responsible for FGF23 cleavage at the furin-like cleavage 
site, and thus inactivation of FGF23, current evidence suggests that the pro-protein 
convertase complex 7B2–PC2 mediates FGF23 degradation104, although this 
proposal needs further confirmation. Expression of the PC2 co-activator 7B2 and the 
active PC2 convertase are reduced in bones from Hyp mice, suggesting that the 
absence of PHEX impairs the cleavage of proPC2 and reduces 7B2–PC2 activity, thus 
providing a potential link between PHEX and FGF23 processing104. This hypothesis is 
supported by the finding that normalization of 7B2 levels in Hyp mice improves bone 
mineralization and increases plasma Pi levels and expression of NaPi-IIa owing to 
normalization (that is, a reduction) of FGF23 levels104. 
MEPE 
MEPE is normally produced by osteoblast and osteocytes and is overexpressed in 
patients with tumour-induced osteomalacia105. MEPE belongs to the SIBLING family 
of proteins, the members of which are all the products of genes located on the same 
chromosome (5q in mouse and 4q in humans). All of these proteins are involved in 
regulating Pi, bone mineralization and extravascular mineralization and contain RGD 
(Arg, Gly and Asp) and ASARM domains. Upon proteolytic cleavage by cathepsin-like 
proteases, free ASARM peptides are released into the circulation. ASARM peptides 
increase plasma FGF23 levels and reduce expression of NaPi-IIa, thereby reducing 
plasma Pi levels and promoting fractional excretion of Pi, consequently inhibiting bone 
mineralization (reviewed elsewhere102). The interaction of PHEX with the ASARM 
domain of MEPE might prevent MEPE proteolysis by cathepsin-like proteases, 
preventing the release of ASARM peptides. PHEX can also bind to and hydrolyse free 
ASARM peptides, thus neutralizing their activity. Serum levels of MEPE-derived 
ASARM peptides are increased in Hyp mice and might contribute to their phosphaturia 
and impaired mineralization106. Administration of MEPE to mice and rats induces 
phosphaturia and reduces the expression of NaPi-IIa without changing the abundance 
of NaPi-IIc107,108. The expression of MEPE in osteocyte-like cells is upregulated by 
extracellular Pi (ref.98), and high dietary Pi increases MEPE expression in 
nephrectomized rats109. In addition, 1,25(OH)2D3 stimulates MEPE expression in 
osteocyte-like cells98 but reduces it in osteoblasts110. 
DMP1 
DMP1 is another SIBLING protein that is produced by osteoblast and osteocytes and 
is overexpressed in patients with OHO111. In addition, DMP1 is mutated in 
patients with autosomal recessive hypophosphataemic rickets (ARHR1; OMIM 
241520)112,113. Patients with ARHR1 present with hypophosphataemia and 
hyperphosphaturia, inappropriately normal levels of 1,25(OH)2D3, high levels of 
FGF23 and severe rickets or osteomalacia, features that are reproduced in DPM1-
deficient mice113. High circulating levels of DMP1-derived ASARM peptides are 
detected in Hyp mice. Deletion of Dpm1 in Hyp mice does not cause additive changes 
in FGF23 or plasma Pi levels as compared with single mutants, indicating that PHEX 
and DMP1 use a common pathway to regulate FGF23 expression114. The expression 
of DMP1 in cultured bone cells is repressed by PTH and 1,25(OH)2D3 (ref.115). 
sFRP4 
sFRP4 is a secreted member of the frizzled family; it is overexpressed (and secreted 
at high levels) in some tumours and associates with tumour-induced osteomalacia and 
OHO116. The physiological effects of sFRP4 probably depend on the extent of 
competition with membrane-bound frizzled receptors for binding to Wnt proteins117. 
Infusion of sFRP4 induces phosphaturia in intact and parathyroidectomized rats, 
paralleled by endocytic retrieval of NaPi-IIa116. Transgenic mice overexpressing 
sFRP4 postnatally have normal serum and urinary Pi levels, high 1,25(OH)2D3 levels 
and high expression of Slc34a1 mRNA, as well as impaired bone mineralization, and 
ablation of sFRP4 in mice does not alter serum or urinary Pi levels118. Thus, sFRP4 
may control bone mineralization but not Pi homeostasis. 
FGF7 
FGF7 is a member of the FGF family of proteins, the members of which are secreted 
by the mesenchyme and contribute to the regulated development of organs, glands 
and limbs119. One study found that levels of FGF7 were upregulated in cultures 
established from OHO-associated tumours and that FGF7 had a potent inhibitory 
effect on Pi transport in renal proximal cells in vitro120. 
NaPi–PDZ protein interactions 
The export and import of NaPi-II cotransporters to and from the cell membrane is 
achieved through interactions with proteins, including several PDZ domain-containing 
proteins121. PDZ domains are ~90 amino acids long, and their most common function 
is the formation of a molecular scaffold that anchors membrane proteins to the 
cytoskeleton122. Using the carboxyl terminus of NaPi-IIa as bait in a yeast two-hybrid 
screen, the first PDZ proteins to be identified as NaPi-IIa partners were NHERF1 
(ref.123) and NHERF3 (refs124,125,126,127). Other PDZ proteins that bind the carboxyl 
terminus of NaPi-IIa are NHERF2 (also known as E3KARP)128, NHERF4 (also known 
as PDZK2), SHANK2 (ref.129) and CFTR-associated ligand (CAL; also known as 
PIST)130 (Fig. 2). 
The carboxyl terminus of NaPi-IIa contains a class I PDZ-binding site, and the three 
amino acids at the end of this region (Thr-Arg-Leu) are necessary for interactions with 
PDZ domain-containing proteins. The three amino acids at the carboxyl terminus of 
NaPi-IIc are Gln-Gln-Leu in humans and in mouse and rat orthologues; this sequence 
enables NaPi-IIc to interact with NHERF1 and NHERF3 but does not enable 
interaction with NHERF2, NHERF4, CAL and SHANK131 (Fig. 2). The interaction of 
NaPi-IIc with NHERF1 is maintained in the absence of the Gln-Gln-Leu motif. 
NHERF1 
NHERF1 contains two PDZ domains and an ezrin-radixin-moesin-binding domain 
(ERM-BD) at the carboxyl terminus that binds to the actin cytoskeleton (Fig. 2). NaPi-
IIa binds only to the first PDZ domain of NHERF1, and this interaction is necessary for 
correct insertion of the cotransporter at the apical membrane132. In fact, targeted 
disruption of NHERF1 in mice reduces the expression of NaPi-IIa at the BBM; causes 
hypophosphataemia and hyperphosphaturia; and attenuates the response of the 
remaining cotransporter to PTH, FGF23 and dietary Pi (ref.133). In agreement with this 
response, PTH and FGF23 phosphorylate NHERF1, causing it to dissociate from 
NaPi-IIa, leading to NaPi-IIa internalization; these actions require the formation of a 
ternary complex involving the PKA-anchoring protein ezrin, NHERF1 and NaPi-IIa134. 
As indicated earlier, NHERF1 also controls the intracellular signalling activated by 
PTH. In the absence of NHERF1, PTH1 receptors in the basolateral membrane of 
renal proximal tubules mostly stimulate PKA-dependent pathways. By contrast, the 
presence of NHERF1 in the apical BBM mediates the physical connection of the 
receptors with PLC, resulting in preferential activation of PLC and PKC39. Activation of 
PKA and PKC (as well as ERK) leads to phosphorylation of NHERF1, thus 
destabilizing its association with NaPi-IIa and enabling the endocytosis of the 
cotransporter19,42. In the intestine, NaPi-IIb interacts with NHERF1 but not with 
NHERF3 (ref.135). NHERF1 is involved in the adaptation of NaPi-IIb to changes in 
dietary Pi concentration. 
NHERF3 
The interaction of NaPi-IIa with NHERF3 has different consequences than the 
interaction with NHERF1. NHERF3 has four PDZ domains (the third of which interacts 
with NaPi-IIa) but lacks an ERM-BD (Fig. 2). Nevertheless, NHERF3 also binds to the 
actin cytoskeleton by interacting with NHERF1 or NHERF2 (ref.136). PTH does not 
phosphorylate NHERF3, suggesting that disassembly of the NaPi-IIa–NHERF3 
complex occurs through different mechanisms than dissociation of NaPi-IIa from 
NHERF1 (ref.137). NHERF3-deficient mice have normal expression of NaPi-IIa at the 
proximal tubule BBM and exhibit normal regulation of NaPi-IIa by PTH and dietary Pi 
(refs21,138). However, NHERF3 seems to stabilize NaPi-IIc in the BBM. Use of 
fluorescence lifetime imaging microscopy and Förster resonance energy transfer 
(FLIM-FRET) demonstrated that the interaction of NHERF1 with NaPi-IIa is much 
stronger than that of NHERF1 with NaPi-IIc, whereas NHERF3 interacts with both with 
the same efficiency138. 
SHANK2E 
SHANK2E is a single PDZ-containing protein that is expressed at the BBM of proximal 
tubules where it interacts with and contributes to the apical retention of NaPi-IIa139,140 
(Fig. 2). Unlike the above-mentioned PDZ partners, SHANK2 redistributes 
intracellularly with NaPi-IIa upon exposure to high Pi levels. 
CAL 
Similar to SHANK2E, CAL is an additional single PDZ-containing protein that interacts 
with NaPi-IIa130,141 (Fig. 2). CAL is mainly located in the trans-Golgi network, where it 
partially colocalizes and interacts with NaPi-IIa. Although it has been proposed to 
retain NaPi-IIa in the trans-Golgi network, the exact role of CAL in the regulation of 
subcellular NaPi-IIa is unclear. 
 
BBM lipid composition and lipid rafts 
The first evidence for a role for lipids in modulating Na–Pi cotransport activity came 
from studies in ageing rats, which exhibit impaired renal tubular Pi transport142. This 
impairment is thought to result from two complementary mechanisms. The first is a 
decrease in the mRNA levels and protein abundance of NaPi-IIa at the tubule epithelial 
BBM63,143. The second mechanism involves post-transcriptional and post-translational 
regulation of NaPi-IIa through alterations in the lipid composition of the BBM. These 
lipid alterations, which particularly involve cholesterol, regulate NaPi-IIa abundance 
and activity through multiple mechanisms that affect processes such as transporter 
trafficking, diffusion and clustering144. 
Levels of cholesterol and sphingomyelin are increased in the tubule epithelial BBM of 
aged rats, and this increase is associated with decreased BBM fluidity as determined 
by measuring the fluorescence anisotropy of diphenylhexatriene. The BBM lipid 
composition and alterations in BBM fluidity also contribute to the impaired renal 
adaptation of NaPi-IIa transporters to a low-Pi diet in aged rats. Adult rats adapt to a 
low-Pi diet by decreasing BBM cholesterol levels and increasing BBM fluidity. In aged 
rats, however, the renal adaptation to a low-Pi diet is incomplete as the ability to lower 
BBM cholesterol and increase BBM fluidity is impaired142. Thus, the increase in BBM 
cholesterol content observed in aged rats and the associated decrease in BBM fluidity 
are important contributors to the impaired renal tubular Pi transport and adaptation to 
a low-Pi diet142. 
In vitro studies show that enrichment of renal BBM with cholesterol directly modulates 
Na–Pi cotransport, inducing a dose-dependent decrease in Na–Pi cotransport activity, 
which is paralleled by decreased BBM fluidity145. Increasing ambient temperature, 
which increases BBM fluidity independent of changes in cholesterol content, increases 
Na–Pi cotransport activity, indicating a direct link between BBM fluidity and Na–Pi 
cotransporter function; however, assessment of Na–Pi cotransport activity as a 
function of BBM fluidity shows that at equivalent BBM fluidities, BBM cholesterol 
enrichment results in a dose-dependent decrease in Na–Pi cotransport activity. 
Moreover, cholesterol enrichment of BBM isolated from rats fed a low-Pi diet 
completely reverses the adaptive increases in Na–Pi cotransport activity and BBM 
fluidity145. 
In line with the above findings, alterations in cellular cholesterol content also directly 
modulate Na–Pi cotransport activity and apical membrane NaPi-IIa protein expression 
in OK kidney tubule cells144. Acute depletion of cholesterol depletion achieved with β-
methyl cyclodextrin results in increased Na–Pi cotransport activity accompanied by a 
moderate increase in apical membrane NaPi-IIa protein abundance and no alteration 
in the total cellular abundance of NaPi-IIa protein. Conversely, acute cholesterol 
enrichment decreases Na–Pi cotransport activity accompanied by a moderate 
decrease in apical membrane NaPi-IIa protein abundance and no change in the total 
cellular abundance of NaPi-IIa protein. By contrast, chronic cholesterol depletion, 
achieved by growing cells in lipoprotein-deficient serum, increases Na–Pi cotransport 
activity and the abundance of apical membrane and total cellular NaPi-IIa protein. 
Chronic cholesterol depletion also increases membrane lipid fluidity and alters lipid 
microdomains as determined by Laurdan fluorescence spectroscopy. Chronic 
cholesterol enrichment, achieved by LDL loading, decreases Na–Pi cotransport 
activity and the abundance of apical membrane and total cellular NaPi-IIa protein. 
Hence, acute and chronic alterations in cholesterol content modulate Na–Pi 
cotransport activity in OK cells through mechanisms that include interactions of NaPi-
IIa with lipid microdomains and the regulation of apical BBM NaPi-IIa protein 
abundance, supporting in vivo observations of the changes that occur in the 
ageing kidney144. 
Studies involving glucocorticoid treatment in mice have revealed additional 
contributions of BBM lipids to the regulation of Na–Pi cotransport activity. 
Administration of dexamethasone to rats decreases the maximal velocity of Na–Pi 
cotransport paralleled by decreases in the abundance of NaPi-IIa mRNA and protein 
and an increase in BBM glucosylceramide content. Reducing BBM glucosylceramide 
content induces an increase in Na–Pi cotransport activity and BBM NaPi-IIa protein 
abundance56, suggesting that the inhibitory effect of dexamethasone on Na–Pi 
cotransport activity might be mediated by an increase in BBM 
glucosylceramide content56. 
Dietary K+ deficiency also increases BBM glucosylceramide content26. As discussed 
earlier, K+ deficiency increases urinary Pi excretion and decreases the maximal 
velocity of BBM NaPi cotransport activity. Surprisingly, the decrease in Na–Pi 
cotransport activity occurs despite an increased abundance of NaPi-IIa protein at the 
BBM26. Of note, the decrease in Na–Pi transport in response to K+ deficiency is 
paralleled by alterations in the lipid composition of the BBM, characterized by 
increases in sphingomyelin, glucosylceramide and ganglioside GM3 content and a 
decrease in BBM lipid fluidity. Inhibition of glucosylceramide synthesis increases BBM 
Na–Pi cotransport activity in control and in K+-deficient rats. These changes in 
transport activity occur independently of changes in BBM NaPi-IIa protein or renal 
cortical Slc34a1 mRNA abundance, suggesting that K+ deficiency in rats inhibits renal 
Na–Pi cotransport activity through post-translational mechanisms that are mediated in 
part by alterations in glucosylceramide content and membrane lipid dynamics26. 
Further studies have investigated the molecular mechanisms by which BBM lipids 
regulate Na–Pi cotransport activity. Fluorescence spectroscopy and multiphoton 
excitation (MPE) fluorescence microscopy using the lipid probe Laurdan have 
revealed the presence of dynamic membrane microdomains, known as lipid rafts in 
the BBM146,147,148,149. Scanning fluorescence correlation spectroscopy (SFCS) 
studies150 show that in response to K+ deficiency, NaPi-IIa partitions in microdomains 
of the apical BBM that are enriched for cholesterol, sphingomyelin and 
glycosphingolipids and that the increased presence of NaPi-IIa in these microdomains 
decreases the activity of the transporter. Importantly, these studies also demonstrated 
that localization of NaPi-IIa in these lipid rafts is associated with decreased lateral 
diffusion of the transporter within the BBM and the formation of NaPi-IIa pentamers 




Clinical consequences of mutations 
Renal Pi losses occur in several systemic syndromes, such as those involving 
generalized inherited or acquired dysfunction of the proximal tubule (for example, 
Fanconi syndrome) and those caused by inherited disorders that specifically affect 
renal and extrarenal Pi regulation. Renal Pi wasting is caused by inactivating mutations 
in SLC34A1 and SLC34A3, which directly reduce renal Pi reabsorption, causing 
nephrocalcinosis and kidney stones. 
SLC34A1 
Several genome-wide association studies (GWAS) have linked single-nucleotide 
polymorphisms in or next to SLC34A1 to serum levels of Pi (ref.151), calcium-
phosphate kidney stones152, hypophosphataemia and low PTH153. 
Mutations in SLC34A1 have been identified in adult patients with kidney stones and 
reduced bone density154, in children with hypophosphataemia and 
hyperphosphaturia155 and in children with infantile idiopathic hypercalciuria156 or with 
nephrocalcinosis and kidney stones153,157,158,159,160,161. Patients from one large family 
with SLC34A1 mutations also showed signs of proximal tubular dysfunction160. Some 
studies have also identified associations between SLC34A1 mutations and metabolic 
acidosis or epilepsy, sensorineural deafness and learning deficiencies162, although 
these manifestations might not be directly linked to mutations in SLC34A1. Larger 
deletions encompassing SLC34A1 are found in patients with Sotos syndrome, which 
is characterized by learning deficiencies, facial dysmorphia, overgrowth, 
hypercalcaemia and nephrocalcinosis163. Unless renal manifestations develop into 
CKD, the clinical symptoms of patients with SLC34A1 mutations seem to improve as 
they enter adulthood. 
To date, 29 mutated sites have been identified in SLC34A1; most of these result in 
missense mutations, small in-frame deletions, frameshifts or early stop 
codons153,154,155,157,158,159,160,161,164. More than half of these mutations affect residues 
located within the highly predicted conserved transmembrane domains of the 
transporter. Functional studies show that several of these mutants have reduced 
transporter function mostly owing to trafficking defects and intracellular retention of the 
transporter156,159,165. One mutation — an in-frame deletion of seven amino acids at the 
cytoplasmic amino-terminal tail (91del7) — has been detected in several patients 
either in compound heterozygosity or in homozygosity. The clinical features of patients 
with this mutation are similar to those of patients carrying other SLC34A1 mutations 
(nephrocalcinosis, hypercalcaemia and hyperphosphataemia)156, suggesting that the 
91del7 mutation is pathogenic. Functional studies show no or only a mild transport 
defect166; however, expression of the mutant transporter at the apical membrane is 
lower than that of wild-type protein, with some intracellular accumulation, together 
suggesting a possible trafficking defect156. Notably, genetic databases such as the 
Exome Aggregation Consortium browser show that this mutation has a high minor 
allele frequency of 0.018, which suggests that nearly 2% of the general population is 
heterozygous for this mutation. This frequency is comparable to the combined allele 
frequency of all proven pathogenic exonic mutations, which is 0.022; the total allele 
frequency of all nucleotide changes that lead to an altered amino acid sequence is 
0.07. Because the impact of carrying only one allele with the 91del7 mutation or other 
mutations is unclear, further clinical studies and mechanistic tests are required. 
Nevertheless, some of the mutations might be associated with a higher risk 
of developing calcium-phosphate kidney stones in adulthood. A genetic study of 
Pakistani families with kidney stones found heterozygous mutations in SLC34A1 in 
several families, which affected the transport activity of the transporter165. Moreover, 
heterozygous SLC34A1 mutations were found in three French patients with kidney 
stones154. 
Most SLC34A1 mutations are homozygous or compound heterozygous with an 
autosomal recessive inheritance of clinical symptoms. The existence of family 
members carrying mutant forms of SLC34A1 but with no clinical abnormalities 
suggests that one mutated allele is not sufficient for disease manifestations to occur. 
This observation is somewhat in contrast to the above-described analyses of 91del7 
allele frequencies, which suggest a link between heterozygous 91del7 mutations and 
the presence of calcium-phosphate stones on the basis of the identification of these 
and similar mutations in cohorts of patients with kidney stone disease. Whether this 
association exists by chance, given that the minor allele frequency of SLC34A1 
mutations is high and that up to 10% of the population suffers at least from one stone 
episode during their lifetime, remains to be clarified. Available data suggest that the 
link between monoallelic SLC34A1 mutations and stone disease risk is complex. In 
one study, three adult patients who presented with calcium-phosphate stones and 
reduced bone density had only one mutated SLC34A1 allele154. By contrast, in another 
study, heterozygous family members of patients with calcium-phosphate stones and 
homozygous mutations in SLC34A1 did not show a higher frequency of kidney stones 
than that of the general population155. Nevertheless, available GWAS clearly support 
an association of SLC34A1 with stone disease153. Because NaPi-IIa forms 
homodimers27,141 in which both subunits function independently167, monoallelic 
mutations could impair the trafficking of NaPi-IIa dimers comprising wild-type and 
mutant proteins, thereby causing a dominant negative effect. Alternatively, the function 
of one normal allele may not be sufficient to adapt renal Pi handling to changing 
metabolic and dietary demands, thereby increasing a carrier’s risk of developing 
kidney stones. 
In mice, ablation of Slc34a1 causes hypophosphataemia resulting from urinary Pi loss 
and is associated with low PTH and FGF23 and higher than normal 1,25(OH)2D3 
levels50,156. NaPi-IIa-deficient mice develop renal calcifications containing calcium 
phosphate and calcium oxalate when fed diets high in Pi or oxalate168,169. Similar to 
human patients with biallelic SLC34A1 mutations, NaPi-IIa-deficient mice are also 
hypercalciuric50,156. Urinary Pi wasting in this context stimulates 1,25(OH)2D3 synthesis 
and inhibits 1,25(OH)2D3 degradation. High levels of 1,25(OH)2D3 stimulate intestinal 
Ca2+ absorption, which promotes nephrolithiasis and calcinosis. Of note, the renal 
calcifications of NaPi-IIa-deficient mice can be reduced by restricting 1,25(OH)2D3 
availability and supplementing Pi levels170. Children with homozygous or compound 
heterozygous mutations in SLC34A1 can improve plasma calcium and phosphate 
levels and growth with Pi supplementation whereas vitamin D3 supplementation can 
be detrimental156. Of major interest for the adult population is the possibility of gene–
diet interactions, whereby the combination of monoallelic mutations with specific Pi, 
Ca2+, oxalate and vitamin D3 exposures might trigger nephrolithiasis. 
SLC34A3 
Biallelic mutations in SLC34A3 cause hereditary hypophosphataemic rickets with 
hypercalciuria (HHRH)171,172,173 (reviewed elsewhere174). Although these patients also 
manifest with hypophosphataemia, hyperphosphaturia, hypercalciuria and elevated 
1,25(OH)2D3 levels, they can be distinguished from patients carrying SLC34A1 
mutations on the basis of their higher risk of rickets. Nearly all patients with HHRH 
develop kidney stones or nephrocalcinosis. Clinical problems often persist into 
adulthood, suggesting that in humans, the contribution of NaPi-IIa is higher in earlier 
phases of life whereas NaPi-IIc might be more important in the adult kidney, although 
long-term follow-up of patients with SLC34A1 and SLC34A3 mutations are needed to 
address this possibility. The exact contribution of both transporters to age-dependent 
renal Pi handling also requires clarification. 
To date, 34 mutations have been identified in SLC34A3 (refs171,172,173,174); most of 
these mutations are missense, alter potential splice sites or generate premature stop 
codons. Only few mutations have been characterized in any detail, and these were 
found to cause retention of NaPi-IIc in the endoplasmic reticulum, reduce its stability 
at the plasma membrane or reduce its transport activity174. According to the ExAC 
database, pathogenic mutations in SLC34A3 (with a minor allele frequency of 0.002) 
are around ten times less frequent than pathogenic mutations in SLC34A1. When 
suspected pathogenic mutations are included in these analyses, the total allele 
frequency of pathogenic mutations in SLC34A3 increases to 1.5%, but this increase 
is mostly due to two very frequent allele variants that have an allele frequency of nearly 
0.4% and 0.8%. The relevance of these variants in terms of NaPi-IIc activity is, 
however, unclear and requires detailed analyses. 
Two mouse models have been generated with constitutive or renal-specific and 
inducible depletion of Slc34a3. Both models show normal growth, normal renal Pi 
handling with normophosphataemia and normal bone growth and morphology175,176. 
Whereas constitutive depletion results in hypercalcaemia with hypercalciuria, high 
levels of 1,25(OH)2D3 and low FGF23 (ref.175), mice with inducible deletion of renal 
Slc34a3 had similar Ca2+ levels in plasma and urine as well as normal 1,25(OH)2D3 
and FGF23. No evidence for compensation by other renal Pi transporters, that is, NaPi-
IIa or PIT2, was found176, suggesting that in adult murine kidney NaPi-IIc is 
dispensable and that mice are not a good model for HHRH. 
SLC34A2 
Biallelic mutations in SLC34A2 have been identified in patients with pulmonary 
alveolar microlithiasis (PAM), which is characterized by progressive deposition of 
calcium-phosphate microcrystals in the lung, subsequent tissue destruction, 
pulmonary fibrosis and insufficiency and in some patients cor pulmonale177,178,179. 
Heterozygous mutations have also been linked to testicular microlithiasis in a few 
patients177, but this association is yet to be confirmed by independent studies. Twenty 
mutations have thus far been reported, comprising deletions, frameshifts and 
missense mutations as well as mutations that induce changes in potential splice sites 
and the promoter region177,178,179, although the functional consequences of these 
mutations on transport activity, trafficking or protein stability have not been well 
characterized. One study demonstrated that at least two truncated SLC34A2 mutants 
do not transport Pi when expressed in Xenopus oocytes179. 
Despite prominent expression of NaPi-IIb in intestine, patients with SLC34A2 
mutations have no known phenotype related to intestinal Pi absorption or systemic Pi 
homeostasis. In addition to its expression in the intestine, NaPi-IIb is also expressed 
in type II pneumocytes in the lung180 — cells that are important for surfactant 
production. A study that expressed one SLC34A2 variant in an alveolar cell line 
demonstrated that Pi transport was diminished, suggesting that NaPi-IIb could have a 
role in controlling extracellular Pi levels in alveolar fluid181. 
Mice with Slc34a3 deletion have been generated, mainly to characterize the role of 
NaPi-IIb in intestine182,183. These models indicate that NaPi-IIb is the main NaPi-II 
cotransporter in the ileum, although depletion of Slc34a3 has only mild consequences 
on Pi and hormonal levels182,183. Mice with deletion of Slc34a3 specifically in lung 
epithelium have increased Pi levels in their bronchoalveolar fluid, together with 
calcium-phosphate microcrystals, invasion of macrophages and signs of inflammation 
and fibrosis184. The microcrystals could be resolved by bronchoalveolar lavage or by 
feeding mice with a low-Pi diet for 4 weeks. Whether these experimental therapies are 
relevant for human patients remains to be shown. 
Mechanism of epithelial Pi transport 
Our current understanding of the transport mechanisms and structure–function 
relationships of NaPi-II transporters has come largely from overexpression studies in 
X. laevis oocytes and the use of voltage clamp, fluorometry and tracer uptake assays. 
This approach has facilitated the characterization of a homogeneous population of 
transporters without contamination from other transmembrane Pi influx pathways as 
can occur when renal or intestinal tissue is used. 
Energetics and kinetics 
All three NaPi-II isoforms are Na+-dependent and preferentially transport divalent Pi 
(HPO42-); however, a key difference between the isoforms is found for NaPi-IIc8: NaPi-
IIa and NaPi-IIb are electrogenic7,185 whereas NaPi-IIc is electroneutral8. A strict 
stoichiometric relationship exists between Na+ and Pi in NaPi-II-mediated transport: 
this ratio is 3:1 for the electrogenic isoforms, resulting in one net positive charge 
transported per cycle186, and 2:1 for NaPi-IIc, resulting in zero net charge 
movement8,187. Thus, the uphill movement of anionic Pi is driven by the 
electrochemical gradient provided by Na+ ions. This gradient is maintained in native 
cells by the Na+/K+-ATPase that is highly abundant at the basolateral membrane. The 
physiological basis for having both electrogenic and electroneutral isoforms expressed 
in the same organ is not known. 
Detailed investigations of the transport properties of the NaPi-II proteins have 
culminated in a kinetic model for NaPi-II-mediated transport188. This model depicts Pi 
transport at the single-molecule level as a cyclic process, comprising a sequence of 
transitions between conformationally distinct states of the protein (Fig. 4a). When the 
empty transporter is in its outward-facing conformation (state 1), two external Na+ ions 
bind sequentially to allow Pi access to the binding site within the carrier (states 2–4). 
A third Na+ ion then binds (state 5) and a translocation event occurs (state 6), allowing 
release of the substrates into the cytosol (state 7 followed by state 0). For NaPi-IIa 
and NaPi-IIb, the rate of return of the empty carrier from state 0 to state 1 is dependent 
on the membrane potential, which results from the movement of charges intrinsic to 
the protein that are displaced by the transmembrane electric field. The release of the 
third Na+ ion into the cytosol is also thought to involve a small charge displacement189. 
The charge movements that are thought to reflect these conformational changes are 
small, amounting to an effective charge of one electron per transport cycle per protein, 
and can be detected only by analysing a large population of independent proteins. The 
charge movements manifest as pre-steady-state current relaxations as the 
transporters respond to rapid changes in membrane potential (Fig. 4b). Similar to the 
gating charges of ion channels, they display properties of nonlinear capacitive 
currents190. When Na+ ions are present in the extracellular medium, the displacement 
charge is increased (Fig. 4c), indicating that an additional movement of charge 
accompanies the molecular rearrangements when Na+ ions bind. These 
conformational changes have been indirectly measured by means of voltage clamp 
fluorometry (VCF)188. When both Na+ and Pi are present, the translocation from 
outward-facing (state 4) to inward-facing (state 5) conformations is an electroneutral 
process. Thus, it is the release of the final Na+ ion that gives rise to the transport-
related Pi-dependent current (IPi) (Fig. 4d). This current is an indirect measure of the 
Pi transport rate, assuming invariant driving force and number of active transporters. 
The voltage dependence of Pi transport in the steady state can be fully accounted for 
by the voltage-dependent kinetics of the empty carrier and steps involving cation 
binding and release. Transport turnover rates based on biophysical measurements 
are estimated to be <10 s−1 at ~20 °C, and the rate-limiting step in the transport cycle 
is thought to be the translocation of the fully loaded carrier. The transport cycle of 
electroneutral NaPi-IIc is essentially the same as for NaPi-IIa and NaPi-IIb, except that 
the first Na+ ion to bind is not translocated and has been hypothesized to act as a 
catalytic activator191. Importantly, neither pre-steady-state relaxations nor steady-state 
Pi-dependent currents are detectable for this isoform, consistent with its 
electroneutrality8,187,191. The molecular basis for electrogenicity has been identified 
and rests on three critical amino acids located deep in the transport domain (Fig. 5), 
one of which is charged in all electrogenic isoforms187 (D224; Fig. 5a). The absence of 
this charge in NaPi-IIc may prevent the translocation of the first Na+ ion192. 
Investigations of transporter function have also assessed substrates other than Na+ 
and Pi. Transport by all isoforms is reduced by acidification of the external medium. 
This reduction is in part due to titration of Pi, which reduces the availability of divalent 
Pi but also arises because protons modulate the kinetics of the empty carrier and 
effectively compete with the final Na+ interaction193,194,195. Use of lithium ions as a 
cationic probe showed that a Li+ ion competes with Na+ for occupancy at the first cation 
binding site. For the electrogenic NaPi-IIb, one Li+ ion can substitute for one of the 
three Na+ ions transported196,197. 
Structure–function relationships 
On the basis of biochemical assays, freeze fracture studies198 and assessment of the 
structurally similar dicarboxylate cotransporter, VcINDY199, it is likely that NaPi-II 
proteins assemble in the membrane as dimers, although each protomer is functionally 
independent200. A 3D crystal structure of NaPi-II proteins or their bacterial homologues 
does not currently exist; however, homology modelling studies192,201 suggest that they 
may have a 3D architecture similar to that of dimeric VcINDY199, which is a member 
of the divalent anion/Na+ symporter (DASS) family. Homology modelling using VcINDY 
as a template has enabled prediction of residues involved in substrate coordination — 
predictions that have been confirmed by analysing the functional consequences of 
single point mutations at these sites192,201. The secondary topology of VcINDY is 
characterized by two inverted repeat units in which each repeated unit contributes to 
the transport and oligomerization domains201 (Fig. 5a). This structure is expected to 
be common to all three NaPi-II isoforms as well as their bacterial homologues, 
consistent with the similarity of their hydrophobicity profiles202. Each repeated unit 
contains stretches of high sequence similarity, and these are predicted to undergo 
conformational changes during transport and to allow substrate accessibility from 
either side of the membrane202, consistent with the alternating access model for 
carrier-mediated membrane transport in which, depending on the state of occupancy, 
substrates can access their binding sites from either the external or internal media but 
not simultaneously203. 
Structure–function studies combined bioinformatics and functional assays using the 
substituted cysteine accessibility (SCAM) technique, crosslinking, chimaeras 
containing complementary elements from NaPi-IIa and NaPi-IIb and site-directed 
mutagenesis to identify functionally important regions188. An inward-facing 
conformation was predicted using the repeat swap strategy previously applied to study 
other carrier proteins, including VcINDY199,204. Comparison of the outward and inward 
conformations suggests that similar to the SLC14 family, SLC34 (NaPi-II) proteins 
most likely mediate transport using the so-called ‘elevator mechanism’, which involves 
an ~37° rotation and 15 Å vertical displacement of the transport domain relative to the 
oligomeric interface domain that acts as a fixed scaffold205 (Fig. 5b). This mechanism 
allows substrates to bind in the outward-facing conformation but does not allow them 
direct access to the cytosol; when fully loaded, the transport domain then translocates 
the substrates by changing to the inward-facing conformation, whereupon the 
substrates are released to the cytosol. The relatively large movements predicted by 
this model have been detected by VCF188. 
Substrates and inhibitors of NaPi 
To date, only two substrates for NaPi transporters — Pi and arsenate — and only a 
handful of competitive inhibitors have been described. The known inhibitors can be 
used to study the characteristics of the Pi transporters and to inhibit their function for 
therapeutic purposes. Some inhibitors are competitive and bind to the same binding 
site as Pi; others are non-competitive and bind in non-Pi-binding parts of the 
transporters206. Here, we focus on the better known and available inhibitors. A more 
complete list can be obtained elsewhere206. 
Phosphonoformic acid 
Phosphonoformic acid (PFA) is the most commonly used competitive inhibitor of Pi 
transport and is also a potent antiviral drug (foscarnet). PFA is structurally very similar 
to Pi (Fig. 6); extending its formate side chain attenuates its inhibitory properties207. 
PFA inhibits Pi transport in rat kidney and jejunum BBMVs with K i values of 0.46 mM 
and 0.37 mM, respectively208. The Ki values for PFA inhibition of rat NaPi-IIa, NaPi-IIb 
and NaPi-IIc expressed in X. laevis were 0.7–1 mM, 0.16 mM and 0.9 mM, 
respectively208. PFA is, however, a very poor inhibitor of PIT1 and PIT2 (ref.209). 
Binding of PFA to NaPi-IIa also prevents Pi-induced currents and Na+ slippage (that 
is, Na+ binding and then leakage inside the cell causing a conductivity rise) at low Pi 
concentration210. 
Administration of PFA either parenterally207,211 or orally212 to rats induces 
phosphaturia, although the effect on phosphataemia is variable. However, the 
nephrotoxicity of PFA impedes its use in patients with CKD-related 
hyperphosphataemia213. 
Arsenate 
Arsenate is also structurally very similar to Pi and is a competitive inhibitor of the NaPi 
members. The affinity of arsenate for NaPi transporters is lower than that of Pi (ref.131), 
exemplified by the finding that the arsenate Ki values in kidney3 and small intestine2 
BBMVs are higher than the Km for Pi transport. Arsenate also mimics Pi most likely 
and interacts with an intracellular Pi sensor in OK kidney cells214. 
NAD 
NAD and its precursor niacin (vitamin B3) also inhibit Pi transport, but the mechanism 
of inhibition is unclear. In vitro studies in renal215 and intestinal216 BBMVs suggest that 
NAD competitively inhibits Pi transport, whereas evidence from in vivo studies 
suggests a non-competitive mechanism215. Nicotinamide and its analogues increased 
the cAMP content in proximal tubule suspensions by 2–5-fold205, but this increase was 
not confirmed in rats in vivo206. NAD induces phosphaturia within 1 h of intraperitoneal 
administration even in animals deprived of dietary Pi (ref.217). An analysis of rats with 
hepatectomy-induced hypophosphataemia and hyperphosphaturia showed 
upregulation of renal nicotinamide phosphoribosyltransferase (Nampt), the rate-
limiting enzyme in NAD biosynthesis, which was accompanied by downregulation of 
NaPi-IIa and NaPi-IIc expression in the proximal tubule218. The same researchers also 
demonstrated a role for Nampt and NAD in regulating circadian variations in Pi levels 
by mediating changes in NaPi-IIa and NaPi-IIc abundance219. 
Tenapanor 
Tenapanor was initially designed as an inhibitor of the intestinal sodium–hydrogen 
exchanger NHE3 but was subsequently found to inhibit intestinal absorption of Pi in 
healthy and nephrectomized rats, attenuating ectopic calcification and 
hyperphosphataemia220. Tenapanor does not, however, inhibit Pi transport. Rather, 
inhibition of NHE3 modulates intestinal tight junctions, leading to increased 
transepithelial electrical resistance, which reduces the paracellular absorption of Pi 
(ref.221). 
PF-06869206 
PF-06869206 is an azaindole analogue and a new selective inhibitor of NaPi-IIa 
developed by Pfizer222. It has an IC50 of 0.4 µM when administered to HEK293 cells 
that express rat or mouse NaPi-IIa and is a poor inhibitor of other Pi transporters. In 
rats, the bioavailability of this drug is very high, but both rats and mice show moderate 
clearance, which is saturated at high drug concentration. The role of PF-06869206 in 
CKD is, however, questionable, because Pi transport and reabsorption are already 
inhibited by high FGF23 plasma concentrations and by PTH, and intestinal absorption 
of Pi remains highly functional223. 
JTP-59557 
The triazole derivative JTP-59557 from Japan Tobacco Inc. was shown to be a non-
competitive inhibitor of intestinal Pi transport in rat BBMVs with a reported IC50 <1 µM, 
and of intestinal absorption ex vivo224. The effects on other Pi transporters is unknown, 
as is the pharmacokinetic behaviour or toxicity. 
ASP3325 
Conflicting results have been reported with use of the chemical ASP3325 (Astellas 
Pharma Inc.) in rats and humans. This drug inhibits rat NaPi-IIb with an IC50 of 88 nM, 
inhibiting intestinal Pi absorption, and improves Pi renal excretion and experimental 
hyperphosphataemia. These benefits have not, however, been observed in human 
patients with hyperphosphataemia225. 
Conclusions 
Over the past quarter century, tremendous progress has been made in our 
understanding of the regulation of NaPi-IIa, NaPi-IIb and NaPi-IIc and their critical role 
in maintaining Pi homeostasis. However, despite this progress, more work is needed 
to determine the mechanisms underlying the differential regulation of these 
transporters in health and disease, particularly in CKD. In addition, the exact 
mechanisms involved in the regulation of intestinal Pi reabsorption also remain an 
enigma. Greater understanding of the molecular mechanisms underlying Pi transport 
and its regulation is likely to lead to the development of additional approaches to target 
specific transporters, which will lead to new treatments for maintaining Pi homeostasis 














Trafficking of the Na+-dependent inorganic phosphate (Pi) cotransporters NaPi-IIa and NaPi-
IIc to and from the brush-border membrane (BBM) of kidney tubular epithelial cells occurs 
through interaction of the transporters with PDZ domain-containing proteins, such as sodium–
hydrogen antiporter 3 regulating factor 1 (NHERF1) and NHERF3. The two renal NaPi 
transporters interact with the NHERF proteins with different affinities: NaPi-IIa has a higher 
affinity for NHERF1 whereas NaPi-IIc has a higher affinity for NHERF3. Parathyroid hormone 
(PTH) downregulates the expression of NaPi-IIa. Binding of PTH to receptors on the 
basolateral membrane of renal proximal tubules preferentially activates adenylyl cyclase 
(AC)–protein kinase A (PKA)-dependent pathways, whereas binding of PTH to apical 
receptors results in preferential activation of phospholipase C (PLC)–protein kinase C (PKC)-
dependent signalling. This differential activation is due to the capacity of NHERF1, expressed 
specifically in the apical BBM, to form a complex with PLC, thus resulting in activation of PKC. 
PKA and PKC signalling converges, at least partially, on extracellular-signal regulated kinases 
(ERKs). Activation of these kinases results in phosphorylation of NHERF1, thereby reducing 
the affinity of NHERF1 for NaPi-IIa and resulting in release of the cotransporter from its 
anchoring partner. Upon disassembly, NaPi-IIa is endocytosed and finally targeted to 
lysosomes where it is degraded. PTH also induces the internalization of NaPi-IIc, but the fate 
and recycling of this transporter are not completely understood. Internalization of both 
cotransporters depends on myosin VI, a minus-end-directed actin motor protein. Microscopy 
studies of transfected opossum kidney cells show that PTH induces more rapid internalization 
of NaPi-IIa and increased diffusion of NaPi-IIa compared with NaPi-IIc. Similar time course 
differences in internalization of NaPi-IIa and NaPi-IIc also occur in mice treated with PTH. 




a | Several PDZ domain-containing proteins exist. Sodium–hydrogen antiporter 3 regulating 
factor 1 (NHERF1) and NHERF2 consist of two PDZ domains and an ezrin-radixin-moesin-
binding domain (ERM-BD), which enables the protein to anchor to the actin-based 
cytoskeleton. NHERF3 and NHERF4 contain four PDZ domains but lack the ERM-BD. 
SHANK2E contains several motifs that mediate protein–protein interaction, including ankyrin 
repeats (AR), an SH3 domain, a PDZ domain, a proline-rich region (PR) and a sterile α-motif 
(αS). The AR interacts with the α-subunit of spectrin, an actin-binding protein. CFTR-
associated ligand (CAL) consists of two coil-coil domains (CC) and a single PDZ domain. PDZ 
domains that interact with NaPi transporters are indicated by asterisks. b | NHERF1, NHERF3 
and SHANK2E are associated with the brush-border membrane, whereas NHERF2 and 
NHERF3 are expressed in subapical vesicles and CAL is expressed in the trans-Golgi 
network. NaPi, Na+-dependent inorganic phosphate cotransporter. 
 
Figure 3 
Na+-dependent inorganic phosphate (Pi) cotransporter NaPi-IIa is present in the apical brush-
border membrane of tubule epithelial cells as a dimer, where it acts as a cotransporter for Na+ 
and divalent Pi (HPO42-). Saturation of lipid membrane microdomains, for example, with ageing 
or cholesterol loading, leads to the formation of lipid rafts, which are characterized by 
increased concentrations of cholesterol and glycosphingolipids within the membrane. NaPi-





a | A kinetic model is shown for the electrogenic isoforms (Na+-dependent inorganic phosphate 
(Pi) cotransporters NaPi-IIa and NaPi-IIb). The cotransport cycle comprises transitions 
between a series of conformations (stages 0–7) that are linked kinetically by partial reactions 
(arrows). Three partial reactions (red) are voltage-dependent and involve charge 
displacements within the transmembrane electric field. All other partial reactions are 
electroneutral (black arrows). For the normal, physiologically relevant cotransport cycle, two 
Na+ ions bind sequentially to the outward-facing empty carrier (state 0), leading to a 
conformational (state 3) that allows Pi binding and a third Na+ ion to bind, leading to the fully 
loaded carrier. A translocation event takes place (states 4–5) and substrates are subsequently 
released (state 0), whereupon the cycle returns to state 1. The displacement of the empty 
carrier intrinsic charge (under the influence of the transmembrane electric field) and charge 
associated with the initial Na+ ion interactions can fully account for the observed voltage 
dependence of the electrogenic NaPi-IIa and/or NaPi-IIb. In the absence of Pi, Na+ ions can 
‘leak’ through the transporter at a low rate (states 2–6)210,226. The order in which substrates 
are released into the cytosol has not been fully determined (indicated by dashed arrows), and 
the charge contribution from the internal Na+ binding transition is small. For the electroneutral 
NaPi-IIc, the transport cycle is similar but the first Na+ ion is not transported, and it is electrically 
silent. b–d | Using experimental manipulations, three unique electrogenic responses have 
been resolved. b | Pre-steady-state current relaxations reflect the empty carrier reorientation 
from inward-facing to outward-facing conformations. c | When Na+ ions are present in the 
extracellular medium, the displacement charge is increased, indicating an additional 
movement of charge. d | When both Na and Pi are present, the transporter is mostly in the 
cotransport mode and the relaxations are strongly suppressed. The release of the final Na+ 
ion gives rise to the transport-related Pi-dependent current (IPi). 
 
Figure 5 
a | Secondary topology of Na+-dependent inorganic phosphate (Pi) cotransporter NaPi-II 
based on homology modelling using the dicarboxylate transporter VcINDY as a template201. 
Two repeat units (RU1 and RU2) contain a number of duplicated amino acids (not shown). 
Rectangular blocks represent α-helical stretches. Transmembrane domains 7 and 8, the large 
extracellular loop linking the two repeat units and amino and carboxyl termini, were not 
included in the homology model. The transport domain regions are coloured orange and the 
oligomerization (scaffold) domain is coloured mauve. Numbering is according to human NaPi-
IIa. The two hairpin loops (HP1a and HP1b, and HP2 and HP2b) are proposed to be involved in 
coordination of the second and third Na+ ions and Pi together with the linkers L2ab and L5ab. 
The three amino acids critical for conferring voltage electrogenicity (A218, A220 and D224) at 
the cytosolic end of TM3 are indicated. b | A 3D model of NaPi-IIb (flounder isoform) in two 
conformations illustrates how the proposed elevator transport mechanism operates205. Only 
one protomer is shown. The scaffold domains of each protomer (shown in purple) would abut 
one another to stabilize the dimeric structure and allow independent movement of the transport 
domains. In the outward conformation site, Na1 is occupied first, followed by Na2, Pi and Na3. 
The inward conformation is reached by vertical displacement and partial rotation of the 
transport domain to allow release of substrates to the cytosol. 
 
Figure 6 
A comparison of the 2D molecular structures of known competitive inhibitors (arsenate and 
phosphonoformic acid (PFA)) shows the structural similarity with inorganic phosphate (Pi). 
Na+-dependent Pi cotransporter NaPi-II can be inhibited by competitive inhibitors, which bind 
to the same binding site as Pi (represented by (1); for example, PFA and arsenate), and non-
competitive inhibitors, which bind to non-Pi-binding sites (represented by (2); for example, 
triazoles and azaindoles). Inhibition of Pi transport can also be achieved by interfering with the 
interaction of Pi transporters with PDZ proteins and inducing rearrangements of the 
transporters and associated proteins in the plasma membrane (3). NAD has been reported to 
have both competitive and non-competitive inhibitor properties and, in vitro, increases 
the intracellular concentration of cAMP, which could potentially inhibit Pi transport (4). 
Tenapanor (not shown) acts by indirect mechanisms, possibly by modulating intestinal 
epithelial tight junctions through its actions on intestinal sodium–hydrogen exchanger NHE3, 
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Glossary 
Micropuncture 
A technique that uses one or more microelectrodes inserted into the 
glomerulus, renal vessels or specific nephron segments of the kidney in situ to 
measure glomerular filtration, blood flow or tubular transport processes. 
Brush-border membrane vesicles 
(BBMVs). Sealed vesicles derived from the brush-border membrane of 
epithelial cells that are frequently used to study the apical transport of solutes 
across the apical membrane in vitro. They are obtained upon homogenization 
of the tissue and precipitation of basolateral membranes with MgCl2. 
Lysosomes 
Intracellular acidic organelles that contain enzymes that are able to hydrolyse 
protein, sugars, lipids, RNA and DNA. These enzymes have an acidic optimal 
pH. Among other substrates, they digest endocytosed material. 
Microtubule 
A component of the cytoskeleton consisting of polymers of tubulin. They are 
involved in several cellular processes, including intracellular transport of cargo 
vesicles to and from the plasma membrane using kinesin or dynein as motor 
proteins. 
Subapical endocytic apparatus 
(SEA). A subapical domain of epithelial cells consisting of clathrin-coated pits, 
endocytic vesicles and membrane-limited tubules called dense apical tubules. 
These tubules have been proposed to contribute to the sorting and recycling of 
endocytic cargo and receptors. 
Total internal reflection fluorescence (TIRF) microscopy 
A technique whereby total internal reflection of the excitation light limits 
fluorescence detection to approximately 100 nm above the glass or the apical 
membrane. 
Modulation tracking 
An orbital tracking method for single particle tracking based on active feedback, 
which moves microvilli to maintain them within the centre of a scanned pattern. 
Raster image correlation spectroscopy 
(RICS). A non-invasive technique that detects and quantifies events in a live 
cell, including the concentration of molecules and diffusion coefficients of 
molecules. 
Number and brightness (N&B) analysis 
A technique based on moment analysis for measuring the average number of 
molecules and brightness in each pixel in fluorescence microscopy images. 
Autosomal dominant hypophosphataemic rickets 
(ADHR). A rare hereditary disease that has an autosomal dominant mode of 
inheritance and variable age of onset and is caused by mutations that increase 
the half-life of FGF23. It is characterized by renal phosphate wasting, 
hypophosphataemia and inappropriately normal levels of 1,25-dihydroxy-
vitamin D3, with patients suffering from bone pain and rickets. 
Tumour-induced osteomalacia 
Also known as oncogenic hypophosphataemic osteomalacia. A rare syndrome 
caused by small tumours that secrete fibroblast growth factor 23 (FGF23), 
matrix extracellular phosphoglycoprotein (MEPE) and secreted frizzled-related 
protein 4 (sFRP4). It is characterized by hypophosphataemia due to urinary 
loss of inorganic phosphate, bone pain and fractures and muscle weakness. 
Familial tumoural calcinosis 
(FTC). Also known as hyperphosphataemic FTC. A rare autosomal hereditary 
disorder characterized by hyperphosphataemia due to inactivating mutations in 
the FGF23, GALNT3 or KL genes and by secondary to reduced urinary 
excretion of inorganic phosphate, normal or elevated 1,25-dihydroxy-vitamin D3 
and ectopic calcification. 
Hypomorphic 
A hypomorphic mutation is one that results in reduced activity of the encoded 
protein. 
Osteoglophonic dysplasia 
A rare autosomal dominant disease caused by mutations in the fibroblast 
growth factor receptor 1 (FGFR1). Patients exhibit hypophosphataemia due to 
hyperphosphaturia and abnormal bone growth that results in severe 
craniofacial abnormalities, short and bowed legs and arms and dwarfism. 
X-Linked hypophosphataemic rickets 
(XLH). An X-linked hypophosphataemic disease secondary to renal loss of 
inorganic phosphate caused by mutations in phosphate-regulating neutral 
endopeptidase (PHEX). Patients suffer from rickets, bone and/or dental 
deformities and have short stature. 
Autosomal recessive hypophosphataemic rickets 
(ARHR1). Similar biochemical and phenotypical features as autosomal 
dominant hypophosphataemic rickets, but with a recessive mode of inheritance. 
It is caused by mutations in DMP1 (among others). 
Fluorescence lifetime imaging microscopy and Förster resonance energy transfer 
(FLIM-FRET). A microscopy system that enables determination of protein–
protein interactions within 10 nm or less in live cells on the basis of changing 
lifetimes of the fluorophores. 
Sphingomyelin 
A phospholipid enriched in saturated fatty acids that is part of the lipid rafts. 
BBM fluidity 
A measure of the lipid dynamics of the apical brush-border membrane. 
Fluorescence anisotropy of diphenylhexatriene 
Measurement of the membrane fluidity. A higher value indicates a less fluid 
membrane. 
Lipid microdomains 
Also known as lipid rafts. Regions of the membrane that may be smaller than 
the 200 nm size of the diffraction barrier and that may be dynamic in nature. 
Laurdan fluorescence spectroscopy 
Laurdan is a fluorescent molecule that is highly sensitive to water penetration 
and cholesterol within the membrane lipid bilayer. 
Glucosylceramide 
A membrane glycosphingolipid that is associated with lipid raft formation. 
Multiphoton excitation (MPE) fluorescence microscopy 
A nonlinear microscopy system in which the exciting light is provided by a two-
photon near-infrared laser. 
Scanning fluorescence correlation spectroscopy 
(SFCS). A technique that performs multiple fluorescence correlation 
spectroscopy measurements simultaneously by rapidly directing the excitation 
laser beam in a uniform (circular) scan across the bilayer of the cell membrane 
in a repetitive fashion. SFCS provides a quantitative and highly sensitive 
method to study protein diffusion and protein–membrane interactions. 
Sotos syndrome 
An inborn syndrome characterized by accelerated body length growth, 
microcephalus and delayed cognitive and motor development. It is caused by 
deletions on chromosome 5q35 encompassing the NSD1 gene neighbouring 
the SLC34A1 gene locus. 
Compound heterozygosity 
Two different recessive mutations of a particular gene. 
Minor allele frequency 
The frequency at which the second most common allele occurs in a given 
population. 
Hereditary hypophosphataemic rickets with hypercalciuria 
(HHRH). An autosomal recessive form caused by mutations in SLC34A3 and 
characterized by reduced renal phosphate reabsorption, hypophosphataemia, 
and rickets. It can be distinguished from other forms of hypophosphataemia by 
increased serum levels of 1,25-dihydroxy-vitamin D3 resulting in hypercalciuria. 
Pulmonary alveolar microlithiasis 
(PAM). A chronic, slowly fibrosing lung disease caused and characterized by 
calcium-phosphate microcrystal depositions in the alveolar space. 
Cor pulmonale 
Right ventricular enlargement secondary to a lung disorder that causes 
pulmonary arterial hypertension. 
Testicular microlithiasis 
An asymptomatic deposition of small crystals in testes. It may be associated 
with the risk of infertility or testicular cancer, but a causal link has not been 
established to date. 
Electrogenic 
A membrane transport process that involves net charge transfer accompanying 
substrate transport. 
Electroneutral 
A membrane transport process that involves no net charge transfer 
accompanying substrate transport. 
Capacitive currents 
Transient currents induced by changes in membrane potential that result from 
charging and discharging the membrane capacitance or displacement of mobile 
charges within the transmembrane electric field. 
Voltage clamp fluorometry 
(VCF). A technique in which time-resolved changes in fluorescence that reflect 
changes in the microenvironment of fluorophores linked to engineered cysteine 
residues at the periphery of the protein are measured. The changes in 
fluorescence can be interpreted as conformational changes induced by the 
membrane potential and cation availability. 
Secondary topology 
The orientation of membrane-spanning segments (for example, α-helices) and 
other secondary structures (for example, linkers and β-sheets) with respect to 
the inner and outer faces of the membrane. 
Substituted cysteine accessibility (SCAM) technique 
A technique used to determine secondary topological features by assessing the 
effect of linking methanethiosulfonate reagents to novel cysteines substituted 
at sites predicted to be of functional importance. 
Repeat swap strategy 
A homology modelling strategy applied to membrane transporters that contain 
repeat units. These are used as templates to predict alternative conformations 
not available from the crystal structure of the homologous protein. 
K i  
The inhibitory constant for competitive inhibitors, which is related to the affinity 
of the inhibitor for the substrate binding site and is independent of the substrate 
concentration. 
Na+ slippage 
An older term used to describe uncoupled Na+ leak current mediated by Na+-
coupled transporters in the absence of substrate (for example, inorganic 
phosphate). 
IC50  
The half-maximal inhibitory concentration — that is, the concentration of 
inhibitor that reduces transport (or other quantifiable physiological process) to 
a half at a specific concentration of the substrate that is being transported. 
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